Advertisement
UK markets close in 3 hours 17 minutes

  • FTSE 100

    8,039.90
    +16.03 (+0.20%)
     

  • FTSE 250

    19,697.44
    +98.05 (+0.50%)
     

  • AIM

    753.62
    +4.44 (+0.59%)
     

  • GBP/EUR

    1.1621
    +0.0032 (+0.27%)
     

  • GBP/USD

    1.2404
    +0.0054 (+0.44%)
     

  • Bitcoin GBP

    53,313.66
    +136.39 (+0.26%)
     

  • CMC Crypto 200

    1,420.27
    +5.51 (+0.39%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.26
    -0.64 (-0.78%)
     

  • GOLD FUTURES

    2,316.60
    -29.80 (-1.27%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,030.32
    +169.52 (+0.95%)
     

  • CAC 40

    8,075.82
    +35.46 (+0.44%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Healthcare group Sanofi forms research deal with the company Exscientia

Reuters
Updated ·1-min read
Sanofi logo is seen in Aramon

PARIS (Reuters) - French healthcare company Sanofi, which has been under pressure to revive its drug pipeline after some setbacks in the COVID-19 vaccine race, announced on Friday a research deal with the company Exscientia to develop new medicines.

The two companies said they would work on developing an artificial-intelligence (AI) driven pipeline of new products in areas such as oncology and immunology.

Exscientia will also receive an upfront cash payment of $100 million with the potential of $5.2 billion in total milestones plus tiered royalties, as part of the deal with Sanofi.

(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)